Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lopinavir/ritonavir sprinkle formulation - Cipla

Drug Profile

Lopinavir/ritonavir sprinkle formulation - Cipla

Alternative Names: Lopimune Sprinkles; Lopinavir/ritonavir mini-melt tablets formulation; Lopinavir/ritonavir oral pellets; Ritonavir/lopinavir

Latest Information Update: 01 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cipla
  • Developer Cipla; Drugs for Neglected Diseases Initiative Foundation
  • Class Amides; Antiretrovirals; Carbamates; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered HIV infections
  • Phase III HIV-1 infections

Most Recent Events

  • 30 Nov 2022 No development reported - Phase-III for HIV-1 infections (In children) in Tanzania (PO) (DNDi pipeline, November 2022)
  • 30 Nov 2022 No development reported - Phase-III for HIV-1 infections (In children) in Uganda (PO) (DNDi pipeline, November 2022)
  • 12 Feb 2022 Efficacy and adverse events data from the phase III LIVING trial in HIV infections presented at the 29th Conference on Retroviruses and Opportunistic Infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top